126 related articles for article (PubMed ID: 38546542)
1. Butyrylcholinesterase-Activated Near-Infrared Fluorogenic Probe for In Vivo Theranostics of Alzheimer's Disease.
Wang L; Sun T; Zhen T; Li W; Yang H; Wang S; Feng F; Chen Y; Sun H
J Med Chem; 2024 Apr; 67(8):6793-6809. PubMed ID: 38546542
[TBL] [Abstract][Full Text] [Related]
2. Development of potent reversible selective inhibitors of butyrylcholinesterase as fluorescent probes.
Pajk S; Knez D; Košak U; Zorović M; Brazzolotto X; Coquelle N; Nachon F; Colletier JP; Živin M; Stojan J; Gobec S
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):498-505. PubMed ID: 31914836
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 4-benzylpiperazinequinoline BChE inhibitor that suppresses neuroinflammation for the treatment of Alzheimer's disease.
Chen Y; Zhang W; Li Q; Xie H; Xing S; Lu X; Lyu W; Xiong B; Wang Y; Qu W; Liu W; Chi H; Zhang X; Feng F; Sun H
Eur J Med Chem; 2024 Jun; 272():116463. PubMed ID: 38704944
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Butyrylcholinesterase-Activated Near-Infrared Fluorogenic Probe for Live-Cell and In Vivo Imaging.
Liu SY; Xiong H; Yang JQ; Yang SH; Li Y; Yang WC; Yang GF
ACS Sens; 2018 Oct; 3(10):2118-2128. PubMed ID: 30203965
[TBL] [Abstract][Full Text] [Related]
5. Butyrylcholinesterase Protein Ends in the Pathogenesis of Alzheimer's Disease-Could
Jasiecki J; Wasąg B
Biomolecules; 2019 Oct; 9(10):. PubMed ID: 31601022
[No Abstract] [Full Text] [Related]
6. Synthesis and Biological Evaluation of New Cholinesterase Inhibitors for Alzheimer's Disease.
Hussein W; Sağlık BN; Levent S; Korkut B; Ilgın S; Özkay Y; Kaplancıklı ZA
Molecules; 2018 Aug; 23(8):. PubMed ID: 30110946
[TBL] [Abstract][Full Text] [Related]
7. Tryptophan-derived butyrylcholinesterase inhibitors as promising leads against Alzheimer's disease.
Meden A; Knez D; Jukič M; Brazzolotto X; Gršič M; Pišlar A; Zahirović A; Kos J; Nachon F; Svete J; Gobec S; Grošelj U
Chem Commun (Camb); 2019 Mar; 55(26):3765-3768. PubMed ID: 30864579
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of selective and potent Carbazole-based butyrylcholinesterase inhibitors.
Ghobadian R; Nadri H; Moradi A; Bukhari SNA; Mahdavi M; Asadi M; Akbarzadeh T; Khaleghzadeh-Ahangar H; Sharifzadeh M; Amini M
Bioorg Med Chem; 2018 Sep; 26(17):4952-4962. PubMed ID: 30190181
[TBL] [Abstract][Full Text] [Related]
9. Butyrylcholinesterase as a Diagnostic and Therapeutic Target for Alzheimer's Disease.
Darvesh S
Curr Alzheimer Res; 2016; 13(10):1173-7. PubMed ID: 27040140
[TBL] [Abstract][Full Text] [Related]
10. A novel near-infrared fluorescent probe for high-sensitivity detection of butyrylcholinesterase in various pathological states.
Jiang Y; Cui H; Yu Q
Spectrochim Acta A Mol Biomol Spectrosc; 2024 Mar; 308():123801. PubMed ID: 38142494
[TBL] [Abstract][Full Text] [Related]
11. Near-Infrared Aggregation-Induced Emission Luminogens for In Vivo Theranostics of Alzheimer's Disease.
Zhang T; Chen X; Yuan C; Pang X; Shangguan P; Liu Y; Han L; Sun J; Lam JWY; Liu Y; Wang J; Shi B; Zhong Tang B
Angew Chem Int Ed Engl; 2023 Jan; 62(2):e202211550. PubMed ID: 36336656
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a butyrylcholinesterase-specific probe via a structure-based design strategy.
Yang SH; Sun Q; Xiong H; Liu SY; Moosavi B; Yang WC; Yang GF
Chem Commun (Camb); 2017 Apr; 53(28):3952-3955. PubMed ID: 28322391
[TBL] [Abstract][Full Text] [Related]
13. Quinoxaline derivatives: novel and selective butyrylcholinesterase inhibitors.
Zeb A; Hameed A; Khan L; Khan I; Dalvandi K; Choudhary MI; Basha FZ
Med Chem; 2014; 10(7):724-9. PubMed ID: 24875826
[TBL] [Abstract][Full Text] [Related]
14. Pharmacophore-based drug design of AChE and BChE dual inhibitors as potential anti-Alzheimer's disease agents.
Gao H; Jiang Y; Zhan J; Sun Y
Bioorg Chem; 2021 Sep; 114():105149. PubMed ID: 34252860
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal evaluation of a novel BChE PET tracer as an early
Rejc L; Gómez-Vallejo V; Joya A; Moreno O; Egimendia A; Castellnou P; Ríos-Anglada X; Cossío U; Baz Z; Passannante R; Tobalina-Larrea I; Ramos-Cabrer P; Giralt A; Sastre M; Capetillo-Zarate E; Košak U; Knez D; Gobec S; Marder M; Martin A; Llop J
Theranostics; 2021; 11(13):6542-6559. PubMed ID: 33995675
[No Abstract] [Full Text] [Related]
16. Design, synthesis, and biological evaluation of aromatic tertiary amine derivatives as selective butyrylcholinesterase inhibitors for the treatment of Alzheimer's disease.
Lu X; Qin N; Liu Y; Du C; Feng F; Liu W; Chen Y; Sun H
Eur J Med Chem; 2022 Dec; 243():114729. PubMed ID: 36084535
[TBL] [Abstract][Full Text] [Related]
17. A far-red/near-infrared fluorescence probe with large Stokes shift for monitoring butyrylcholinesterase (BChE) in living cells and in vivo.
Zhang WD; Zhang JM; Qin CZ; Wang XR; Zhou YB
Anal Chim Acta; 2022 Dec; 1235():340540. PubMed ID: 36368817
[TBL] [Abstract][Full Text] [Related]
18. The exploration of thienothiazines as selective butyrylcholinesterase inhibitors.
Karlsson D; Fallarero A; Brunhofer G; Mayer C; Prakash O; Mohan CG; Vuorela P; Erker T
Eur J Pharm Sci; 2012 Aug; 47(1):190-205. PubMed ID: 22683890
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis of Alzheimer's Disease and
Yang Y; Zhang L; Wang J; Cao Y; Li S; Qin W; Liu Y
Anal Chem; 2022 Oct; 94(39):13498-13506. PubMed ID: 36121878
[TBL] [Abstract][Full Text] [Related]
20. Contemporary medicinal-chemistry strategies for the discovery of selective butyrylcholinesterase inhibitors.
Jing L; Wu G; Kang D; Zhou Z; Song Y; Liu X; Zhan P
Drug Discov Today; 2019 Feb; 24(2):629-635. PubMed ID: 30503804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
